Sofosbuvir/Daclatasvir

DRUG4 trials

Sponsors

Shin Poong Pharmaceutical Co. Ltd., University of Witwatersrand, South Africa, ANRS, Emerging Infectious Diseases, National Liver Institute, Egypt

Conditions

COVID-19Covid19HCV InfectionHepatitis C,Chronic Children, OnlySARS-CoV Infection

Phase 2

Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

CompletedNCT04532931

Shin Poong Pharmaceutical Co. Ltd.COVID-19

Start: 2020-09-03End: 2021-08-23Updated: 2025-07-28

COVID-19 Prophylaxis South Africa (COVER HCW)

CompletedNCT04561063

University of Witwatersrand, South AfricaCovid19, SARS-CoV Infection

Start: 2020-12-08End: 2022-02-28Updated: 2022-06-07

Unknown Phase

Study of DAA Treatment for Children and Adolescents With Active HCV Infection in Cambodia

Active, not recruitingNCT05992077

ANRS, Emerging Infectious DiseasesHCV Infection

Start: 2023-08-07End: 2026-01-31Target: 21000Updated: 2025-12-04

Twelve Weeks Sofosbuvir/Daclatasvir in HCV Infected Children Aged 6-18 Years

CompletedNCT07905989

National Liver Institute, EgyptHepatitis C,Chronic Children, Only

Start: 2023-12-18End: 2024-07-25Updated: 2026-10-30

Related Papers

Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

Trials2022-07-227 citations